Gopal Krishna, MD
Nephrology · Salinas, CANPI 1073692083
Payments from drug & device makers
Across 949 payments — averaging $759.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$409K
- GSK$97K
- Ardelyx, Inc.$82K
- CSL Behring$41K
- AstraZeneca$30K
- Vifor Pharma, Inc.$28K
- plus $34K from 24 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 304 | $409,181 |
| GSK | 25 | $96,512 |
| Ardelyx, Inc. | 33 | $81,849 |
| CSL Behring | 29 | $40,714 |
| AstraZeneca(2 entities) | 81 | $30,096 |
| Vifor Pharma, Inc. | 164 | $28,171 |
| Janssen Research & Development, LLC | 1 | $12,416 |
| Fresenius USA Marketing, Inc. | 111 | $6,909 |
| Aurinia Pharma U.S., Inc. | 6 | $6,365 |
| Bayer | 20 | $4,208 |
| Amgen(2 entities) | 46 | $1,041 |
| Travere Therapeutics, Inc. | 8 | $512 |
| Novartis | 8 | $502 |
| OPKO Pharmaceuticals, LLC | 32 | $467 |
| Calliditas Therapeutics US Inc. | 37 | $443 |
| Otsuka America Pharmaceutical, Inc. | 14 | $316 |
| Mallinckrodt Hospital Products Inc. | 8 | $200 |
| Abbott | 2 | $167 |
| Novo Nordisk | 4 | $71 |
| Boehringer Ingelheim | 2 | $40 |
| Kyowa Kirin, Inc. | 2 | $40 |
| AMAG Pharmaceuticals, Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $38 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Covidien LP | 1 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
How this compares
$720,439 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Salinas
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.